Factor This Power Engineering
Live Events
DTECH® Events
POWERGENâ¢
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Podcasts
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by BeOne Medicines Ltd.
BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia
July 31, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Tickers
ONC
BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment
July 28, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Tickers
ONC
BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6
July 16, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Tickers
ONC
European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma
July 10, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Tickers
ONC
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
June 26, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Tickers
ONC
BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®
June 25, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Tickers
ONC
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025
June 12, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Tickers
ONC
U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications
June 11, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Tickers
ONC
BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025
June 11, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Tickers
ONC
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025
June 02, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Tickers
ONC
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
May 31, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Tickers
ONC
BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology
May 27, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Tickers
ONC
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.